Home

Lexaria Bioscience Corp. - Warrant (LEXXW)

0.2605
-0.0295 (-10.17%)
SummaryNewsPress ReleasesChartHistorical
Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseasesbenzinga.com
Via Benzinga · May 23, 2023
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levelsbenzinga.com
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) (NASDAQ: LEXXW) diabetes animal model study DIAB-A22-1 has been completed and produced at least three positive outcomes including weight loss in
Via Benzinga · March 2, 2023
Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Eventsbenzinga.com
Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4
Via Benzinga · July 27, 2022
Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antiviralsbenzinga.com
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via Benzinga · April 22, 2022
Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Datebenzinga.com
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via Benzinga · April 20, 2022
Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Studybenzinga.com
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via Benzinga · April 13, 2022
Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Programbenzinga.com
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via Benzinga · March 16, 2022